Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC)

被引：0
|
作者：
Salud, A.
Escudero, P.
Feliu, J.
Lopez-Gomez, L.
Bolanos, M.
Galan, A.
Yubero, A.
Vicent, J. M.
Losa, F.
Gonzalez-Baron, M.
机构：
[1] Hosp Arnau Vilanova, Med Oncol Serv, Lleida, Spain
[2] Hosp Lozano Blesa, Med Oncol Serv, Zaragoza, Spain
[3] Hosp La Paz, Med Oncol Serv, Madrid, Spain
[4] Hosp Virgen Salud, Med Oncol Serv, Toledo, Spain
[5] Hosp San Pedro Alcantara, Med Oncol Serv, Caceres, Spain
[6] Hosp Sagunto, Med Oncol Serv, Valencia, Spain
[7] Hosp Obispo Polanco, Med Oncol Serv, Teruel, Spain
[8] Hosp Gen Univ, Med Oncol Serv, Valencia, Spain
[9] Hosp Creu Roja De Barcelona, Med Oncol Serv, Barcelona, Spain
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：190 / 190
页数：1
相关论文
共 50 条
  • [31] Phase II study of capecitabine plus oxaliplatin (XELOX) followed by capecitabine plus irinotecan (XELIRI) in a sequential schedule in first-line metastatic colorectal cancer (MCRC)
    Cassinello, Javier
    Alvarez, Jose V.
    Garcia Lopez, Maria J.
    Pujol, Eduardo
    Colmenarejo, Antonio
    De Segovia, Fernando
    Marcos, Fernando
    Filipovich, Elena
    Arcediano, Alberto
    Garcia Castro, Ines
    ANNALS OF ONCOLOGY, 2006, 17 : 116 - 117
  • [32] OXALIPLATIN PLUS CAPECITABINE (XELOX) AS FIRST-LINE CHEMOTHERAPY FOR ELDERLY PATIENTS WITH ADVANCED GASTRIC CANCER: RESULTS OF A MONOCENTRIC EXPERIENCE
    Rozzi, A.
    Corona, M.
    Nardoni, C.
    Restuccia, M.
    Lanzetta, G.
    ANNALS OF ONCOLOGY, 2009, 20 : 90 - 90
  • [33] Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    J Feliu
    J Barriuso
    British Journal of Cancer, 2011, 104 : 226 - 226
  • [34] Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’
    M J Molina-Garrido
    C Guillén-Ponce
    British Journal of Cancer, 2011, 104 : 224 - 225
  • [35] Comment on 'Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer'
    Molina-Garrido, M. J.
    Guillen-Ponce, C.
    BRITISH JOURNAL OF CANCER, 2011, 104 (01) : 224 - 225
  • [36] Sequential capecitabine-based treatment of patients with metastatic colorectal cancer (MCRC) combined with oxaliplatin first-line: A retrospective analysis.
    Hoeffkes, HG
    Arland, M
    Freidank, A
    Ranze, O
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 277S - 277S
  • [37] Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    Feliu, J.
    Barriuso, J.
    BRITISH JOURNAL OF CANCER, 2011, 104 (01) : 226 - 226
  • [38] (XELOX) capecitabine plus oxaliplatin: Clinical efficacy and safety in the first-line treatment for metastatic gastric cancer
    Manuguerra, G.
    Alu, M.
    Leonardi, V.
    Laudani, A.
    Palmisano, V.
    Pepe, A.
    Arcuri, C.
    Savio, G.
    Cusimano, M.
    Calabria, C.
    Porretto, C.
    de Bella, M. Tamburo
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 5 - 5
  • [39] (XELOX)Capecitabine plus Oxaliplatin: clinical efficacy and safety in first-line treatment for metastatic gastric cancer
    Alu, M.
    Laudani, A.
    Leonardi, V.
    Palmisano, V.
    Savio, G.
    Pepe, A.
    Arcuri, C.
    Cusimano, M. R.
    Calabria, C.
    Agostara, B.
    EJC SUPPLEMENTS, 2007, 5 (04): : 273 - 273
  • [40] A phase II study of capecitabine plus oxaliplatin (XELOX)A new first-line option in metastatic colorectal cancer
    Thomas Makatsoris
    Haralabos P. Kalofonos
    Gerasimos Aravantinos
    Christos Papadimitriou
    Efstathios Kastritis
    Sotirios K. Rigatos
    Nikolaos Xiros
    Theodore Petsas
    Theofanis Economopoulos
    Athanassios K. Sakadamis
    George Fountzilas
    International Journal of Gastrointestinal Cancer, 2005, 35 (2): : 103 - 109
12345